Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 114 followers
Latest posts
Last updated 4 days ago
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers
4 days ago
December 3, 2025 For Release : Immediately Refer to: Carrie Munk; munk_carrie@lilly.com...
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
4 days ago
Approval is based on results from the BRUIN CLL-321 trial, the only...
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials
6 days ago
Lilly continues efforts to expand access for people living with obesity by...
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
13 days ago
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone...
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
13 days ago
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib)...
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
18 days ago
Gateway Labs model provides lab space and tailored scientific engagement to fuel...
Lilly to participate in Citi's 2025 Global Healthcare Conference
19 days ago
INDIANAPOLIS , Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)...
Statement: Eli Lilly has no affiliation with Mangoceuticals, Inc.
24 days ago
Eli Lilly and Company (NYSE: LLY) has no affiliation with Mangoceuticals, Inc...
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
27 days ago
New innovative campaign weaves science and storytelling to help reframe obesity as...
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
about 1 month ago
INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
about 1 month ago
Medicare beneficiaries with obesity or overweight will have access to Zepbound and...
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
about 1 month ago
Based on these trial results, Lilly will begin enrolling Phase 3 clinical...